GSK plc Receives US Approval for Antibiotic Utebzi

GSK plc announced on June 17, 2026, that the U.S. Food and Drug Administration (FDA) has approved its antibiotic, Utebzi (tebipenem pivoxil). The drug is indicated for adults with complicated urinary tract infections (cUTIs).

Annually, over three million cases of cUTIs are treated in the United States. Up to one-third of these infections are caused by bacteria resistant to common antibiotics, highlighting a significant unmet medical need. The FDA approval of Utebzi offers a new treatment option for patients facing these challenging resistant infections.

In other recent developments, GSK announced on June 9, 2026, an agreement to acquire Nuvalent, Inc., a move expected to enhance sales and profitability. The company's investigational treatment bepirovirsen for chronic hepatitis B has shown promising results, with development accelerated through a collaboration with China-based SBP Group.

GSK's portfolio continues to expand with other regulatory successes. The RSV vaccine Arexvy has received expanded approval in Japan for a wider age range. Furthermore, the company is presenting new oncology research and pipeline data at major medical conferences, showcasing advancements in its cancer drug development.